End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,38,400 KRW | +0.80% | +7.12% | -42.57% |
21/03 | Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
05/01 | South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing | MT |
Chart calendar Medy-Tox Inc.
Upcoming events on Medy-Tox Inc.
Past events on Medy-Tox Inc.
21/03/2024 | Q4 2023 Earnings Release |
08/11/2023 | Q3 2023 Earnings Release |
07/08/2023 | Q2 2023 Earnings Release |
15/05/2023 | Q1 2023 Earnings Release |
21/03/2023 | Q4 2022 Earnings Release |
14/11/2022 | Q3 2022 Earnings Release |
12/08/2022 | Interim 2022 Earnings Release |
16/05/2022 | Q1 2022 Earnings Release |
23/03/2022 | FY 2021 Earnings Release |
13/08/2021 | Interim 2021 Earnings Release |
17/05/2021 | Q1 2021 Earnings Release |
23/03/2021 | FY 2020 Earnings Release |
30/03/2020 | FY 2019 Earnings Release |
14/11/2019 | Q3 2019 Earnings Release |
15/05/2019 | Q1 2019 Earnings Release |
14/08/2018 | Interim 2018 Earnings Release |
14/02/2018 | FY 2017 Earnings Release |
Past dividends on Medy-Tox Inc.
26/09/2023 | Interim Payment 1100 KRW |
29/09/2022 | Interim Payment 1000 KRW |
29/09/2021 | Interim Payment 1000 KRW |
28/09/2020 | Interim Payment 1000 KRW |
27/09/2019 | Interim Payment 800 KRW |
27/09/2018 | Interim Payment 900 KRW |
27/12/2017 | Final Payment 1400 KRW |
28/09/2017 | Interim Payment 800 KRW |
28/12/2016 | Final Payment 1300 KRW |
29/09/2016 | Interim Payment 700 KRW |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Billions KRW | Released Forecast Spread | 206 203 1.29% | 141 141 -0.33% | 185 181 1.95% | 195 192 1.41% | 221 220 0.48% | 252 |
EBITDA Billions KRW | Released Forecast Spread | 44,3 63,3 -30.02% | -19,1 -19,0 -0.48% | 51,9 47,2 9.82% | 62,0 52,9 17.06% | 32,7 42,4 -22.91% | 71,0 |
EBIT Billions KRW | Released Forecast Spread | 25,7 44,7 -42.47% | -37,1 -38,8 4.56% | 34,5 37,3 -7.65% | 46,7 37,9 23.01% | 17,3 29,9 -41.98% | 54,6 |
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | 25,1 43,6 -42.27% | -42,1 -30,2 -39.61% | 129 152 -14.7% | 49,3 62,6 -21.26% | 15,7 34,4 -54.21% | 55,8 |
Net income Billions KRW | Released Forecast Spread | 26,2 38,8 -32.51% | -29,0 -23,0 -25.99% | 96,2 110 -12.76% | 37,6 49,2 -23.67% | 9,64 24,6 -60.82% | 43,4 |
EPS KRW | Released Forecast Spread | 4 172 5 907 -29.37% | -4 841 -3 438 -40.8% | 15 243 17 115 -10.94% | 5 750 5 629 2.16% | 1 311 3 634 -63.93% | 6 336 |
Announcement Date | 04/03/20 | 12/03/21 | 11/03/22 | 07/03/23 | 07/03/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Billions KRW | Released Forecast Spread | 45,7 41,4 10.2% | 39,8 | 49,8 46,0 8.1% | 53,3 46,3 15.14% | 52,3 51,4 1.76% | 42,7 48,4 -11.83% | 51,8 53,5 -3.2% | 58,7 56,7 3.4% | 68,0 66,9 1.59% | 59,7 | 58,6 | 61,8 | 70,1 |
EBIT Billions KRW | Released Forecast Spread | 0,56 3,42 -83.58% | 10,4 8,09 28.28% | 14,5 8,59 69.1% | 16,3 13,0 25.66% | 1,77 11,5 -84.63% | 9,55 11,7 -18.13% | 3,58 10,7 -66.43% | 2,43 15,0 -83.85% | 9,60 | 11,8 | 15,2 | 18,1 | |
Earnings before Tax (EBT) Billions KRW | Released Forecast Spread | -19,7 4,85 -505.96% | 24,2 8,40 188.37% | 17,6 8,50 106.91% | 2,31 15,0 -84.57% | 9,15 8,90 2.83% | 3,43 12,0 -71.31% | -3,38 10,2 -133.09% | 11,0 | 12,2 | 14,9 | 18,1 | ||
Net income Billions KRW | Released Forecast Spread | -107 3,23 -3420.45% | 19,2 6,15 212.75% | 13,2 8,25 60.1% | -0,57 11,8 -104.83% | 8,98 7,10 26.46% | -2,32 9,55 -124.32% | 12,1 8,80 37.24% | 8,40 | 9,30 | 11,4 | 13,9 | ||
EPS KRW | Released Forecast Spread | 639 | ||||||||||||
Announcement Date | 11/03/22 | 16/05/22 | 12/08/22 | 09/11/22 | 07/03/23 | 15/05/23 | 07/08/23 | 08/11/23 | 07/03/24 | - | - | - | - |
06/05/2024 04:30 pm | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
07/05/2024 | BIOTEST AG: Q1 2024 Earnings Release |
07/05/2024 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
07/05/2024 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
07/05/2024 11:30 am | BIOGAIA AB: Q1 2024 Earnings Release |
07/05/2024 05:00 pm | INTRA-CELLULAR THERAPIES, INC.: Q1 2024 Earnings Release |
08/05/2024 | CATALYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
08/05/2024 | ZAI LAB LIMITED: Q1 2024 Earnings Release |
08/05/2024 05:25 pm | VERICEL CORPORATION: Q1 2024 Earnings Release |
09/05/2024 | NXERA PHARMA CO., LTD.: Q1 2024 Earnings Release |
Past sector events for Medy-Tox Inc.
03/05/2024 01:35 am | TWIST BIOSCIENCE CORPORATION: Q2 2024 Earnings Release |
02/05/2024 05:20 pm | ARBUTUS BIOPHARMA CORPORATION: Q1 2024 Earnings Release |
02/05/2024 05:00 pm | BRIDGEBIO PHARMA, INC.: Q1 2024 Earnings Release |
02/05/2024 | SK BIOSCIENCE CO.,LTD.: Q1 2024 Earnings Release |
30/04/2024 04:30 pm | INCYTE CORPORATION: Q1 2024 Earnings Release |
30/04/2024 | SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.: Q4 2023 Earnings Release |
30/04/2024 | SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD.: Q1 2024 Earnings Release |
30/04/2024 | BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED: Q4 2023 Earnings Release |
30/04/2024 03:23 am | SINOVAC BIOTECH LTD.: Q4 2023 Earnings Release |
29/04/2024 | SHANGHAI OPM BIOSCIENCES CO., LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- A086900 Stock
- Calendar Medy-Tox Inc.